We cut '24e-'26e sales by 5-3% on outlook downgrade Delays should result in pent-up demand Share is ...
CEO Jean Marie Mognetti participated in ABGSC Fireside Chat Focus on strategy, positioning and oppor...
Sales ramp-up continues (187% y-o-y), +13% vs. ABGSCe Positive EBIT (SEK 324k vs.
Roc Oil Company bids SEK 58.7/sh for Tethys Oil Offer in-line with ABGSC valuation, independent comm...
Redeye comments on the lowered expectations of the primary endpoint in the ongoing phase 3 trial.
Biovica records consecutive quarterly IVD test sales growth of 40-50%, with good prospects ahead.
Redeye comments on Oncopeptides’ licensing deal for Pepaxti in South Korea.
Redeye leaves a note following Coegin’s recent announcements of a signed Joint Development Agreement...
Administer’s recent profitability strides signal a promising turn, with the potential for the new st...
Marimekko’s CMD offered more insights into the company’s SCALE strategy for 2023-2027 and its progre...
Redeye comments on its latest insights regarding regulatory development in India, partly about the r...
The new contract with a cardiology clinic includes over 1,300 Medicare patients and the progress str...
Nu är arbetet med att starta guldbrytning i Fäbodtjärn i full gång efter att alla tillstånd är på pl...
Redeye provides a brief comment on the changes to CLS’ board of directors.
Aspo’s results have seen ups and downs in recent years, but the stabilized environment and recent in...
Redeye comments on Vitec carrying out a directed share issue of cSEK1.
CEO, Christoffer Abramson, leaves the companyDaniel Gorosch, CEO of Corporate Finance Sweden, steps ...
Scanfil changes reporting segments to geographical units in 2025.
Redeye comments on an early readout from the intraocular biodistribution study of laquinimod that is...
Redeye endorses SenzaGen’s new grant from RIFM, valued at SEK3.
